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Figure 1: H&E staining of isograft, IL-17 KO allograft and allograft (x100) 
 
Isograft: Normal parenchyma IL-17 KO Allograft: No fibrotic plugs (OB), 
lymphocytic bronchiolitis, normal paren-
chyma 
Allograft: Fibrotic plugs (OB arrows), 
lymphocytic bronchiolotis, abnormal 
parenchyma. 
Isografts (n=4) had a completely normal lung histology. Allografts (n=4) showed OB, LB and abnormal 
parenchyma conform the established model. In the IL-17 KO allografts (n=4), however, no OB could be 
identified. LB lesions were still present, but less pronounced and lung parenchyma was almost normal.  
Chronic rejection lesions are decreased in IL-17 KO allografts, providing the ultimate proof of involve-
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Aim: The only alternative to Total Parenteral Nutrition (TPN) for complicated intestinal failure is Intesti-
nal Transplantation (ITx) which is perceived as a high-risk procedure with inferior results compared to 
other organ Tx. Therefore ITx has been rarely applied in Belgium. In a multicenter retrospective review, 
we analyzed the overall Belgian experience with ITx. 
Methods: The Belgium Liver Intestine Committee organized a survey among all Belgian Tx centers, 
based on the patient-specific data form of the international ITx registry. Overall activity and indications 
were reviewed. Patient/graft survival was calculated (Kaplan-Meier). Nutritional (TPN) independence 
and Quality of Life (QoL) (Karnofsky score) were analyzed. 
Results: 21 ITx were performed in 20 patients (03/99-11/12), distributed among 5 centers: KUL (12), 
ULg (5), UZG (2), UCL (1), UZA (1). Median age was 38y(8mo-56y). Male/female ratio was 10/10. 5 
were pediatrics (<18y) and 15 adults. Indications were anatomical or functional short bowel syndrome: 
intestinal ischemia(5), volvulus(5), Crohn(2), chronic intestinal pseudo-obstruction(2), splanchnic 
thrombosis(2), Churg-Strauss(1), necrotizing enterocolitis(1), microvillus inclusion(1), intestinal 
atresia(1) and chronic rejection of a first ITx(1). Most patients also suffered from TPN-associated com-
plications (infection/shortage of venous access or liver failure). An isolated small bowel was trans-
planted in 9 patients (plus kidney Tx in 2; plus pancreas Tx in 1); 10 received a combined liver and ITx; 
2 received a multivisceral Tx. At time of Tx, 11 patients were hospitalized and 10 at home. 20 grafts 
were procured from deceased donors; one segmental intestinal graft was procured from a living donor. 
ABO blood group was identical in 63%, compatible in 37%. Median cold ischemia time was 
5h30´(3h17´-9h31´). All patients received tacrolimus-based immunosuppression. Basiliximab (anti-IL2 
receptor antibody) induction was administered in 16 patients. In 11 patients donor specific blood was 
transfused as part of an immunomodulatory protocol. 5-year patient and graft survival is 59% and 
55.6%, respectively. 8 patients died: 6 to sepsis, 1 to intracerebral hemorrhage; 1 sudden death re-
mained unexplained. 1 patient developed postTx lymphoma. 2 chronic rejections occured for which one 
reTx was performed. Of 12 survivors (median follow-up 1870 days), 11 are nutritionally independent 
(TPN-free) and 10 have a Karnofsky score >90%. 
Conclusions: ITx has come of age in Belgium. During the last 13 years, 21 ITx were performed in 5 
centers. A 5-year patient/graft survival of 59%/55.6% is achieved, which is similar to results reported by 
the International ITx registry. In Belgium, awareness should grow that ITx represents a life-saving (and 
QoL improving) treatment in selected patients with reduced life expectancy due to significant complica-
tions from TPN and intestinal failure.  
  
